Advanced Non Small Cell Lung Cancer With Kras G12c Mutation clinical trials

Explore recruiting advanced non small cell lung cancer with kras g12c mutation clinical trials.

Recruiting advanced non small cell lung cancer with kras g12c mutation studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Non Small Cell Lung Cancer With Kras G12c Mutation trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation

Germany, Romania, Hungary, Italy, Czechia, France +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Hungary, Poland, Spain, France, Italy, Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non Small Cell Lung Cancer with KRAS G12C Mutation

Portugal, Germany, Bulgaria, Ireland, Poland, Italy +13 more

Phase II and Phase III (Integrated) EU CTIS Study details

Advanced Non Small Cell Lung Cancer With Kras G12c Mutation trials by city

Advanced Non Small Cell Lung Cancer With Kras G12c Mutation in Toronto Advanced Non Small Cell Lung Cancer With Kras G12c Mutation in Vancouver Advanced Non Small Cell Lung Cancer With Kras G12c Mutation in Montreal Advanced Non Small Cell Lung Cancer With Kras G12c Mutation in Calgary Advanced Non Small Cell Lung Cancer With Kras G12c Mutation in Edmonton Advanced Non Small Cell Lung Cancer With Kras G12c Mutation in Ottawa Advanced Non Small Cell Lung Cancer With Kras G12c Mutation in Winnipeg Advanced Non Small Cell Lung Cancer With Kras G12c Mutation in Quebec City Advanced Non Small Cell Lung Cancer With Kras G12c Mutation in Hamilton Advanced Non Small Cell Lung Cancer With Kras G12c Mutation in Kitchener Advanced Non Small Cell Lung Cancer With Kras G12c Mutation in London Advanced Non Small Cell Lung Cancer With Kras G12c Mutation in Halifax Advanced Non Small Cell Lung Cancer With Kras G12c Mutation in New York Advanced Non Small Cell Lung Cancer With Kras G12c Mutation in Los Angeles Advanced Non Small Cell Lung Cancer With Kras G12c Mutation in Chicago Advanced Non Small Cell Lung Cancer With Kras G12c Mutation in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease